World Library  
Flag as Inappropriate
Email this Article


Article Id: WHEBN0002132287
Reproduction Date:

Title: Etodolac  
Author: World Heritage Encyclopedia
Language: English
Subject: List of MeSH codes (D03), Phenylbutazone, Miroprofen, Polmacoxib, Tolfenamic acid
Publisher: World Heritage Encyclopedia


Systematic (IUPAC) name
(RS)-2-(1,8-Diethyl-4,9-dihydro-3H-pyrano[3,4-b]indol-1-yl)acetic acid
Clinical data
Pregnancy cat.
  • C
Legal status
Routes oral
Pharmacokinetic data
Protein binding 100%
Metabolism liver
Half-life 7.3 ± 4.0 hours
Excretion renal
CAS number  YesY
ATC code M01
ChemSpider  YesY
Chemical data
Formula C17H21NO3 
Mol. mass 287.35 g/mol
Physical data
Melt. point 145–148 °C (293–298 °F)
Solubility in water 3.92e-02 mg/mL [ALOGPS] mg/mL (20 °C)
Generic brand of etodolac

Etodolac is a nonsteroidal anti-inflammatory drug (NSAID) approved by the U.S. Food and Drug Administration in January 1991.[1]


  • Action 1
  • Indications 2
  • Interactions 3
  • Pregnancy and nursing 4
  • Side effects 5
  • Brand names 6
  • References 7
  • External links 8


NSAIDs are used for the management of mild to moderate pain, fever, and inflammation. They work by reducing the levels of prostaglandins, which are chemicals that are responsible for pain and the fever and tenderness that occur with inflammation. Etodolac blocks the cyclooxygenase (abbrev. COX) enzymes which form prostanoids, resulting in lower concentrations of prostaglandins. As a consequence, inflammation, pain and fever are reduced.

Post-marketing studies demonstrated that etodolac inhibition of cyclooxygenase is somewhat COX-2 selective [2] similar to celecoxib and other "COX-2 inhibitors." Unlike rofecoxib, both etodolac and celecoxib can fully inhibit COX-1 and are designated as having "preferential selectivity" toward COX-2. The (inactive against COX) r-enantiomer of etodolac inhibits beta-catenin levels in hepatoma cells.[3]


Etodolac is licensed for the treatment of inflammation and pain caused by osteoarthritis and rheumatoid arthritis.[4]


Etodolac should be avoided by patients with a history of asthma attacks, hives, or other allergic reactions to aspirin or other NSAIDs. Rare but severe allergic reactions have been reported in such individuals. It also should be avoided by patients with peptic ulcer disease or poor kidney function, since this medication can worsen both conditions. Etodolac is used with caution in patients taking blood thinning medications (anticoagulants), such as warfarin (Coumadin), because it increases the risk of bleeding. Patients taking both lithium and etodolac may develop toxic blood lithium levels. Additionally, etodolac has been found to interact with certain anti-depressant medications, such as sertraline or fluoxetine, which can increase risks of stroke, heart attack, and other cardiovascular conditions. Patients also taking ciclosporin (Sandimmune) can develop kidney toxicity. Use in children has not been adequately studied. Etodolac is not habit-forming. NSAIDs should be discontinued prior to elective surgery because of a mild interference with clotting that is characteristic of this group of medicines. Etodolac is best discontinued at least four days in advance of surgery.

Persons who have more than 3 alcoholic beverages per day are at increased risk of developing stomach ulcers when taking etodolac or other NSAIDs.

Box, strip and tablet of etodolac (Lodine SR) 600mg

Pregnancy and nursing

Etodolac is generally avoided during pregnancy and nursing. NSAIDs may cause adverse cardiovascular effects in the fetus during pregnancy. [1]

Side effects

Etodolac may cause side effects, or adverse drug reactions. It is advised to contact a physician if any of these symptoms are severe or persistent: Constipation, diarrhea, gas or bloating, vomiting, headache, dizziness, ringing in the ears, runny nose, sore throat, blurred vision.

Some side effects can be serious. It is advised if any of the following symptoms occur to immediately contact a physician, and to discontinue use until such a time:

Unexplained weight gain, swelling of the eyes, face, lips, tongue, throat, hands, feet, ankles, or lower legs, fever or chills, blisters, rash, itching, hives, hoarseness, difficulty breathing or swallowing, yellowing of the skin or eyes, excessive tiredness, unusual bleeding or bruising, lack of energy, loss of appetite, pain in the upper right part of the stomach, flu-like symptoms, pale skin, fast heartbeat, cloudy, discolored, or bloody urine, difficult or painful urination, back pain.

Brand names

Etodolac is manufactured by Almirall Limited under the trade name Lodine SR[5] and by Meda Pharmaceuticals under the name Eccoxolac.[6] Non-proprietary etodolac is also available [7]

The drug is also sold under several other brand names, including:


  1. ^ a b
  2. ^
  3. ^ Behari, J; Zeng, G; Otruba, W; Thompson, MD; Muller, P; Micsenyi, A; Sekhon, SS; Leoni, L; Monga, SP (2007). "R-Etodolac Decreases Beta-Catenin Levels Along with Survival and Proliferation of Hepatoma Cells". Journal of hepatology 46 (5): 849–57.  
  4. ^ BNF 55 - Etodolac
  5. ^ Summary of Product Characteristics Lodine SR
  6. ^ Summary of Product Characteristics Eccoxolac
  7. ^ BNF 55: Etodolac preparations
  8. ^

External links

  • DrugBank info
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.